TrialCirculation. Arrhythmia and electrophysiology2023

Multicenter, Phase 2, Randomized Controlled Study of the Efficacy and Safety of Etripamil Nasal Spray for the Acute Reduction of Rapid Ventricular Rate in Patients With Symptomatic Atrial Fibrillation (ReVeRA-201).

A John Camm et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.